AI spots drugs that may be repurposed for priority pathogen
Researchers have used AI algorithms to sift through thousands of drug molecules and identify some with activity against problem pathogen S pneumoniae.
FDA unveils framework for its expedited IND pilot
The FDA has published the design of its expedited Investigational New Drug pilot, part of a plan to restore US competitiveness in clinical research.
FDA backs Curium's Bexlutry as 1st 'radioligand equivalent'
Curium's copycat version of Novartis GEP-NET therapy Lutathera, Bexlutry, is the first radioligand equivalent (RLE) to be approved by the FDA.
Electra sets terms for IPO, hoping to raise up to $347m
Electra Therapeutics has moved ahead with plans for an IPO, seeking to raise funds for its drug for the rare and life-threatening disease sHLH.
GSK wagers $750m on Chimagen multiple myeloma therapy
GSK has continued a drive to bulk up its pipeline, taking global rights to a T-cell engager for multiple myeloma, developed by China's Chimagen Bio.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
RNA-Targeted Small Molecules: From Discovery to Clinic
Leading pharma, biotech and academic experts discuss the future of RNA therapeutics.
Novel CNS Biomarkers Summit Europe
Europe is rapidly becoming a hub for next-generation CNS biomarker innovation
Who's Speaking at the DIA-MHRA Global Summit 2026?
See who's speaking when regulators and industry convene at the DIA-MHRA Global Summit
4th Cell Therapy for Autoimmune Disease Summit
Developers are racing to overcome challenges around safety, scalability, durability of response, and patient access
10th Complement-Based Drug Development Summit
Uniting leaders pioneering complement-targeted therapies across ophthalmology, neurodegeneration, nephrology, oncology and autoimmune indications